DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Fosaprepitant Dimeglumine is a drug marketed by Apotex Inc, Baxter Hlthcare Corp, Be Pharms, Fresenius Kabi Usa, Lupin Ltd, Msn Labs Pvt Ltd, Mylan Labs Ltd, Sungen Pharma, and Teva Pharms Usa. and is included in nine NDAs.
The generic ingredient in FOSAPREPITANT DIMEGLUMINE is fosaprepitant. There are eleven drug master file entries for this compound. One supplier is listed for this compound. There are two tentative approvals for this compound. Additional details are available on the fosaprepitant profile page.
Summary for FOSAPREPITANT DIMEGLUMINE
Recent Clinical Trials for FOSAPREPITANT DIMEGLUMINE
Identify potential brand extensions & 505(b)(2) entrants
|National Cancer Institute (NCI)||Phase 3|
|Alliance for Clinical Trials in Oncology||Phase 3|
|Merck Sharp & Dohme Corp.||Phase 2|
Recent Litigation for FOSAPREPITANT DIMEGLUMINE
Identify potential future generic entrants
District Court Litigation
|MERCK SHARP & DOHME CORP. v. MSN LABORATORIES PRIVATE LTD.||2018-01-16|
|MERCK SHARP & DOHME CORP. v. ACCORD HEALTHCARE, INC. USA||2012-06-01|
|MERCK SHARP & DOHME CORP. v. SANDOZ INC.||2012-05-31|